Some Astrocytes Appear to Promote Progressive MS
October 2014 Researchers have identified a key enzyme in astrocytes that turns on during the progressive stage of multiple sclerosis,…
Opexa Therapeutics to Present at Cleveland Clinic’s 12th Annual Medical Innovation Summit
October 20, 2014 THE WOODLANDS, Texas–(BUSINESS WIRE)– Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune…
Stuart Schlossman
Secondary Progressive Multiple Sclerosis (SPMS) in Australia
The MIS416 trial is a clinical research trial now enrolling patients with Secondary Progressive Multiple Sclerosis (SPMS) in Australia. Full…
Stuart Schlossman
Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova
MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in…
Stuart Schlossman
The Science of MS Management: Update on Progressive Forms of Multiple Sclerosis
The Science of MS Management: Update on Progressive Forms of Multiple SclerosisCorey C. Ford, MD, PhD; Emmannuelle Waubant, MD, PhD…
Stuart Schlossman
New study will explore potential treatment (ibudilast )for progressive MS
PDF At this time, there is a significant gap in available treatment options for people living with progressive MS. The…
Stuart Schlossman
Different Goals, But a Continued Role, For Neurologists In Late Secondary Progressive MS
R. Philip Kinkel, MD Neurologists can and should continue to play an important role in the care of patients with…
Stuart Schlossman
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis
THE WOODLANDS, Texas–(BUSINESS WIRE)– May 13, 2014 Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel…
Stuart Schlossman
Tcelna Study for the Treatment of Secondary Progressive Multiple Sclerosis (MS)
Dr Daniel Kantor speaks with Dr Edward Fox from the MS Clinic in Central Texas, about the Tcelna study for…
Stuart Schlossman
PPMS Update: Slowing Down Primary Progressive Multiple Sclerosis Disability Progression Worth Safety Risks For New Drugs, Say Surveyed U.S. Neurologists
Posted by: Mike Nace April 11, 2014 Photo Credit: Designua/Shutterstock According to a recent wide-ranging survey among U.S.based neurologists who treat Multiple Sclerosis,…
Stuart Schlossman
